Cargando…
Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma
Tryptophan metabolism is important to induce immune tolerance in tumors. To date, 3 types of tryptophan‐metabolizing enzymes have been identified: indoleamine 2,3‐dioxygenase 1 and 2 (IDO1 and IDO2) and tryptophan 2,3‐dioxygenase 2. Numerous studies have focused on IDO1 as its expression is enhanced...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778659/ https://www.ncbi.nlm.nih.gov/pubmed/31444833 http://dx.doi.org/10.1111/cas.14179 |
_version_ | 1783456802110701568 |
---|---|
author | Yamasuge, Wakana Yamamoto, Yasuko Fujigaki, Hidetsugu Hoshi, Masato Nakamoto, Kentaro Kunisawa, Kazuo Mouri, Akihiro Nabeshima, Toshitaka Saito, Kuniaki |
author_facet | Yamasuge, Wakana Yamamoto, Yasuko Fujigaki, Hidetsugu Hoshi, Masato Nakamoto, Kentaro Kunisawa, Kazuo Mouri, Akihiro Nabeshima, Toshitaka Saito, Kuniaki |
author_sort | Yamasuge, Wakana |
collection | PubMed |
description | Tryptophan metabolism is important to induce immune tolerance in tumors. To date, 3 types of tryptophan‐metabolizing enzymes have been identified: indoleamine 2,3‐dioxygenase 1 and 2 (IDO1 and IDO2) and tryptophan 2,3‐dioxygenase 2. Numerous studies have focused on IDO1 as its expression is enhanced in various cancers. Recently, IDO2 has been identified as a tryptophan‐metabolizing enzyme that is involved in several immune functions and expressed in cancers such as pancreatic cancer. However, the biological role of IDO2 in the induction of immune tolerance in tumors has not yet been reported. In the present study, we examined the effects of Ido2 depletion on tumor growth in a mouse model of Lewis lung carcinoma by using Ido2‐knockout mice. Ido2‐knockout mice had reduced tumor volumes compared to WT mice. Furthermore, Ido2 depletion altered the tumor microenvironment, such as tryptophan accumulation and kynurenine reduction, leading to enhancement of immune cell invasion. Finally, enzyme‐linked immunospot assay revealed that Ido2 depletion enhanced γ‐interferon secretion in the tumor. In conclusion, Ido2 is an important immune regulator in the tumor microenvironment. Our data indicate that IDO2 is a potential target for cancer treatment and drug development. |
format | Online Article Text |
id | pubmed-6778659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67786592019-10-11 Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma Yamasuge, Wakana Yamamoto, Yasuko Fujigaki, Hidetsugu Hoshi, Masato Nakamoto, Kentaro Kunisawa, Kazuo Mouri, Akihiro Nabeshima, Toshitaka Saito, Kuniaki Cancer Sci Original Articles Tryptophan metabolism is important to induce immune tolerance in tumors. To date, 3 types of tryptophan‐metabolizing enzymes have been identified: indoleamine 2,3‐dioxygenase 1 and 2 (IDO1 and IDO2) and tryptophan 2,3‐dioxygenase 2. Numerous studies have focused on IDO1 as its expression is enhanced in various cancers. Recently, IDO2 has been identified as a tryptophan‐metabolizing enzyme that is involved in several immune functions and expressed in cancers such as pancreatic cancer. However, the biological role of IDO2 in the induction of immune tolerance in tumors has not yet been reported. In the present study, we examined the effects of Ido2 depletion on tumor growth in a mouse model of Lewis lung carcinoma by using Ido2‐knockout mice. Ido2‐knockout mice had reduced tumor volumes compared to WT mice. Furthermore, Ido2 depletion altered the tumor microenvironment, such as tryptophan accumulation and kynurenine reduction, leading to enhancement of immune cell invasion. Finally, enzyme‐linked immunospot assay revealed that Ido2 depletion enhanced γ‐interferon secretion in the tumor. In conclusion, Ido2 is an important immune regulator in the tumor microenvironment. Our data indicate that IDO2 is a potential target for cancer treatment and drug development. John Wiley and Sons Inc. 2019-09-25 2019-10 /pmc/articles/PMC6778659/ /pubmed/31444833 http://dx.doi.org/10.1111/cas.14179 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yamasuge, Wakana Yamamoto, Yasuko Fujigaki, Hidetsugu Hoshi, Masato Nakamoto, Kentaro Kunisawa, Kazuo Mouri, Akihiro Nabeshima, Toshitaka Saito, Kuniaki Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title | Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title_full | Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title_fullStr | Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title_full_unstemmed | Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title_short | Indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma |
title_sort | indoleamine 2,3‐dioxygenase 2 depletion suppresses tumor growth in a mouse model of lewis lung carcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778659/ https://www.ncbi.nlm.nih.gov/pubmed/31444833 http://dx.doi.org/10.1111/cas.14179 |
work_keys_str_mv | AT yamasugewakana indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT yamamotoyasuko indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT fujigakihidetsugu indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT hoshimasato indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT nakamotokentaro indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT kunisawakazuo indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT mouriakihiro indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT nabeshimatoshitaka indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma AT saitokuniaki indoleamine23dioxygenase2depletionsuppressestumorgrowthinamousemodeloflewislungcarcinoma |